NCT06751485

JSKN003 in Platinum-Resistant, Relapsed Epithelial Ovarian Cancer

A Randomized, Open-Label, Parallel-Controlled, Multi-center Phase Ⅲ Study of JSKN003 Versus Investigator-Choice Chemotherapy for Platinum-Resistant, Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

• Status: Not Yet Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 430 (estimated)
• Sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd · Industry
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is a randomized, open-label, controlled, phase III study to evaluate the efficacy and safety of JSKN003 versus investigator's choice of chemotherapy in patients with platinum-resistant, relapsed epithelial Ovarian, primary peritoneal, or fallopian tube cancer.

Conditions

• Ovarian Cancer
• Primary Peritoneal
• Fallopian Tube Cancers

Interventions

Type	Name	Description
DRUG	JSKN003	Experimental drug
DRUG	Doxorubicin	Active Comparator
DRUG	Paclitaxel	Active Comparator
DRUG	Topotecan	Active Comparator

Timeline

• Start date: 2025-01-15
• Primary completion: 2026-12-30
• Completion: 2027-12-30
• First posted: 2024-12-30
• Last updated: 2024-12-31